COMMUNIQUÉS West-GlobeNewswire

CARBIOS : Bilan semestriel du contrat de liquidité confié à Natixis ODDO BHF
08/07/2025
COMMUNIQUÉ DE PRESSE INFORMATION REGLEMENTEE : PERMANENTE Titre concerné : Carbios (code ISIN FR0011648716) Marché concerné : Euronext Growth Paris Clermont-Ferrand (France), le 08 juillet 2025 (18h00 CEST). CARBIOS, ( [...]
Report on Carbios’ liquidity contract with Natixis ODDO BHF
08/07/2025
PRESS RELEASE REGULATED INFORMATION: ONGOING Shares concerned: Carbios (ISIN code: FR0011648716) Market concerned: Euronext Growth Paris Clermont-Ferrand (France), 08 July 2025 (18:00 CEST). CARBIOS , (Euronext Growth [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2025
08/07/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 30 juin au 04 juillet 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2025
08/07/2025
Aggregated presentation by day and by market Statement of transactions in own shares from June 30th to July 4th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the transaction [...]
From Stem Cells to CAR-T: LivMedCell Expands Its Role in the Future of Medicine
08/07/2025
Photo: LivMedCell via FL Communications ISTANBUL, July 08, 2025 (GLOBE NEWSWIRE) -- LivMedCell has officially launched a groundbreaking research collaboration with the University of Pennsylvania’s Perelman School of [...]
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds
08/07/2025
WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with [...]
Diagonal Therapeutics Appoints John Lee, M.D., Ph.D., as Chief Medical Officer
08/07/2025
Biotech veteran will lead clinical development of Diagonal’s clustering antibody pipeline, including DIAG723 for hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) WATERTOWN, Mass., [...]
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich’s Ataxia
08/07/2025
Nonclinical findings provide evidence of the mechanism of action of nomlabofusp and support the potential use of skin FXN concentrations as a novel surrogate endpoint for Larimar’s planned BLA submission in Q2 2026 [...]
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
08/07/2025
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third [...]
Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
08/07/2025
Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study to a Phase 2b placebo-controlled study. This is a critical step required prior to proceeding to [...]
Jade Biosciences to Participate in Two Upcoming Investor Conferences
08/07/2025
SAN FRANCISCO and VANCOUVER, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune [...]
Crescent Biopharma Appoints Jan Pinkas, Ph.D., as Chief Scientific Officer
08/07/2025
Seasoned Leader Brings Deep Experience in Oncology Drug Development as Company Advances Portfolio of Next Generation Therapeutics for Solid Tumors WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, [...]
Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases
08/07/2025
Substantial clinical need expected to facilitate rapid overall trial enrollment HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company [...]
BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
08/07/2025
52% of BriaCell’s most-recent 25-patient cohort* have surpassed the one-year survival milestone, exceeding current standard of care in similar patients 11 patients remain alive as of recent contact, including one [...]
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis
08/07/2025
ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine ( [...]
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
08/07/2025
Drug-drug interaction (“DDI”) clinical studies help identify the potential for side effects, or in some cases, reduced therapeutic efficacy, that may be caused by interactions between different drugs. The market leading [...]
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
08/07/2025
MIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (“OPKO”) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that their abstract “First-in-Class Oral GLP-2 Analog for [...]
iCAD Announces Proxy Advisory Firms ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Acquisition by RadNet, Inc.
08/07/2025
NASHUA, N.H., July 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) (“iCAD” or the “Company”), a global leader in clinically proven AI-powered cancer detection solutions, today announced that leading independent [...]
Vaxart Announces Trading on OTCQX Best Market
08/07/2025
SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on [...]

Pages